13 February 2024: Original Paper
A Retrospective Study of Long-Term Outcomes in 16 ABO-Incompatible Deceased Donor Pediatric Liver Transplants from a National Transplant Center at Helsinki University Hospital, Finland, 1987–2022
Timo Jahnukainen 1ABCDEFG* , Inna Sareneva 2CD , Jouni Lauronen 2DE , Elisa Ylinen 1DE , Juuso Tainio 1BCE , Arno Nordin 3BDE , Maria Hukkinen 4BE , Mikko P. Pakarinen 4AE , Hannu Jalanko 1ADEDOI: 10.12659/AOT.941929
Ann Transplant 2024; 29:e941929
Table 2 Use of therapeutic plasma exchange before and after liver transplantation and immunosuppression regimens in pediatric liver transplant patients with an ABO-incompatible liver transplant in Finland.
| Induction therapy, n (%) | ||
|---|---|---|
| Methylprednisolone | 16 (100) | |
| Methylprednisolone + basiliximab | 6 (42.9) | |
| Methylprednisolone + antithyroglobulin | 5 (35.7) | |
| Tacrolimus + azathioprine + glucocorticoid | 2 (12.5) | 2 (12.5) |
| Tacrolimus + mycophenolate + glucocorticoid | 4 (25) | 2 (12.5) |
| Tacrolimus + glucocorticoid | – | 2 (12.5) |
| Tacrolimus monotherapy | – | 1 (6.3) |
| Cyclosporine A + azathioprine + glucocorticoid | 8 (50) | 2 (12.5) |
| Cyclosporine A + mycophenolate + glucocorticoid | 1 (6.3) | 3 (18.8) |
| Cyclosporine A + azathioprine | – | 1 (6.3) |
| Cyclosporine A + glucocorticoid | 1 (6.3) | 2 (12.5) |
| Plasma exchange before LT | 2 (12.5) | |
| Plasma exchange after LT | 3 (18.8) | |
| LT – liver transplantation. | ||